Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.

Fernando Magro,Susana Lopes,Marco Silva,Rosa Coelho,Francisco Portela,Diogo Branquinho,Luis M. Correia,Samuel Raimundo Fernandes,Marília Cravo,Paulo Caldeira,Helena Tavares de Sousa,Marta Patita,Paula Lago,Jaime A. Ramos,Joana Afonso,Isabel Redondo,Patrícia Machado,George Philip,Joanne Lopes,Fátima Carneiro

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.

2019

Background:Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of...

Keywords:

Gastroenterology
Internal medicine
Golimumab
Diabetes mellitus
Ulcerative colitis
Medicine
Biomarker (medicine)
Receptor
Pathology
in patient
moderate to severe

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations